LH
Labcorp Holdings Inc. · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 88.13K | $17.42M | n/a | n/a |
| Q2 2026 | 158 | +5 | 56.54M | $15.82B | +9 | −3 |
| Q1 2026 | 155 | +1 | 55.32M | $14.74B | +4 | −4 |
| Q4 2025 | 153 | -1 | 61.82M | $15.50B | +1 | −1 |
| Q3 2025 | 19 | 0 | 33.10M | $9.50B | n/a | −1 |
| Q2 2025 | 17 | -1 | 30.31M | $7.95B | +1 | −2 |
| Q1 2025 | 15 | +2 | 7.94M | $1.85B | +2 | n/a |
| Q4 2024 | 13 | 0 | 9.58M | $2.20B | +2 | −2 |
| Q3 2024 | 12 | +1 | 4.32M | $962.67M | +2 | −1 |
| Q2 2024 | 11 | n/a | 5.93M | $1.21B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 29.38K | -78.8% | $9.05M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 2 | Wealth Enhancement Advisory… | 57.78K | +3.0% | $8.07M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | TD Waterhouse Canada Inc. | 977 | +69.3% | $297,448 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,014 holders, 76.41M shares, $19.36B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 3.00K sh · $954,060
Officer, Director · 4.67K sh · $1.50M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology